Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.65 |
| ▸ | CTSB | P07858 | 10/20 | 0.64 |
| ▸ | CTSL | P07711 | 9/20 | 0.64 |
| ▸ | CTSF | Q9UBX1 | 8/20 | 0.64 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21690134 | 1.00 | CTSK (0.65) | CTSKCTSBCTSLCTSFCTSS | |
| SCHEMBL21645298 | 1.00 | CTSK (0.65) | CTSKCTSBCTSLCTSFCTSS | |
| SCHEMBL3762636 | 1.00 | CTSK (0.65) | CTSKCTSBCTSLCTSFCTSS | |
| SCHEMBL16105826 | 0.89 | CTSK (0.64) | CTSKCTSBCTSLCTSFCTSS | |
| SCHEMBL17585395 | 0.86 | CTSB (0.57) | CTSKCTSBCTSLCTSFCTSS | |
| SCHEMBL2947335 | 0.84 | CTSL (0.64) | CTSKCTSBCTSLCTSFCTSS | |
| SCHEMBL2947331 | 0.84 | CTSL (0.64) | CTSKCTSBCTSLCTSFCTSS | |
| SCHEMBL2948347 | 0.84 | CTSB (0.60) | CTSKCTSBCTSLCTSFCTSS | |
| SCHEMBL2948349 | 0.84 | CTSB (0.60) | CTSKCTSBCTSLCTSFCTSS | |
| SCHEMBL14579995 | 0.83 | CTSL (0.53) | CTSKCTSBCTSLCTSFCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225196-B1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK CANADA INC (CA) | 2015-01-28 | — | — | EP | claimed |
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | MERCK FROSST CANADA LTD. (CA) | 2010-12-02 | — | — | US | claimed |
| EP-2225196-B1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK CANADA INC (CA) | 2015-01-28 | — | — | EP | disclosed |
| US-8642799-B2 | Cysteine protease inhibitors for the treatment of parasitic diseases | MERCK CANADA INC. (CA) | 2014-02-04 | — | — | US | disclosed |
| US-20130244962-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK FROSST CANADA LTD. (CA) | 2013-09-19 | — | — | US | disclosed |
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | MERCK FROSST CANADA LTD. (CA) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | CTSL, SERPINB1, CTSZ | CTSK 46/4885CTSB 24/4885CTSL 1/4885 |
| US-20130244962-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | CTSL, SERPINB1, CTSZ | CTSK 57/4885CTSB 35/4885CTSL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.